We first engaged Solubility in July 2015 at the recommendation of our key investor groups. Our primary focus at the time was to secure experienced corporate counsel in the standing up of a new Australian subsidiary. We were assigned a client liaison and worked with the firm extensively on what was to become a very successful venture. Over the last 4 years, the firm has been responsive to all of our corporate needs and matters as a Delaware C-Corp. Importantly the lawyers and associates at Solubility worked very hard to understand our technology and the mechanism of action of our drug so that they could provide practical solutions to complicated contracting issues. We cannot recommend a better partner and legal counsel for a biotechnology company doing business in Australia than Solubility.